Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESAT6-CFP10 Dose Finding for TB Diagnosis
NCT02336542Phase 2Completed
- Sponsor
- Zhifei Biological
- Start
- Nov 2014
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, double-blind trial of C-Tb in Tuberculosis (TB) (2 arms), sponsored by Zhifei Biological. Primary endpoints: Diameter of induration or redness within 72 hours after intradermal injection with ESAT6-CFP10, Proportion of positive reaction within 72 hours after administered intradermally TB-PPD and 1 more. Started Nov 2014; status: completed.
02
Drugs
C-Tb
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02336542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336542.